Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients

被引：23

作者：

Aoude, Lauren G. ^{[1
]}

Wong, Bernadette Z. Y. ^{[2
,3
]}

Bonazzi, Vanessa F. ^{[1
]}

Brosda, Sandra ^{[1
]}

Walters, Shaun B. ^{[4
]}

Koufariotis, Lambros T. ^{[5
]}

Naeini, Marjan M. ^{[5
]}

Pearson, John, V ^{[5
]}

Oey, Harald ^{[1
]}

Patel, Kalpana ^{[1
]}

Bradford, Julia J. ^{[1
]}

Bloxham, Conor J. ^{[1
]}

Atkinson, Victoria ^{[6
,7
]}

Law, Phillip ^{[2
]}

Strutton, Geoffrey ^{[8
]}

Bayley, Gerard ^{[6
]}

Yang, Samuel ^{[6
]}

Smithers, B. Mark ^{[6
,7
]}

Waddell, Nicola ^{[5
]}

Miles, Kenneth ^{[2
]}

Barbour, Andrew P. ^{[1
,6
]}

机构：

[1] Univ Queensland, Diamantina Inst, Woolloongabba, Qld, Australia

[2] Princess Alexandra Hosp, Dept Med Imaging, Woolloongabba, Qld, Australia

[3] Gold Coast Univ Hosp, Dept Med Imaging, Southport, Qld, Australia

[4] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia

[5] QIMR Berghofer Med Res Inst, Herston, Qld, Australia

[6] Princess Alexandra Hosp, Queensland Melanoma Project, Woolloongabba, Qld, Australia

[7] Univ Queensland, Fac Med, St Lucia, Qld, Australia

[8] Princess Alexandra Hosp, Dept Anat Pathol, Woolloongabba, Qld, Australia

来源：

MOLECULAR CANCER RESEARCH | 2021年 / 19卷 / 06期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

METASTATIC MELANOMA; SURVIVAL;

D O I：

10.1158/1541-7786.MCR-20-1038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment for metastatic melanoma includes targeted and/or immunotherapy. Although many patients respond, only a subset has complete response. As late-stage patients often have multiple tumors in difficult access sites, non-invasive techniques are necessary for the development of predictive/prognostic biomarkers. PET/CT scans from 52 patients with stage III/IV melanoma were assessed and CT image parameters were evaluated as prognostic biomarkers. Analysis indicated patients with high standard deviation or high mean of positive pixels (MPP) had worse progression-free survival (P = 0.00047 and P = 0.0014, respectively) and worse overall survival (P = 0.0223 and P = 0.0465, respectively). Whole-exome sequencing showed high MPP was associated with BRAF mutation status (P = 0.0389). RNA-sequencing indicated patients with immune "cold" signatures had worse survival, which was associated with CT biomarker, MPP4 (P = 0.0284). Multiplex immunofluorescence confirmed a correlation between CD8 expression and image biomarkers (P = 0.0028).

引用

页码：950 / 956

页数：7

共 22 条

[1] [Anonymous], 2018, CA: A Cancer Journal for Clinicians, V68, P394
[2] Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
Aoude, Lauren G.
Bonazzi, Vanessa F.
Brosda, Sandra
Patel, Kalpana
Koufariotis, Lambros T.
Oey, Harald
Nones, Katia
Wood, Scott
Pearson, John, V
Lonie, James M.
Arneil, Melissa
Atkinson, Victoria
Smithers, B. Mark
Waddell, Nicola
Barbour, Andrew P.
[J]. SCIENTIFIC REPORTS, 2020, 10 (01)
[3] The tumour immune landscape and its implications in cutaneous melanoma
Attrill, Grace H.
Ferguson, Peter M.
Palendira, Umaimainthan
Long, Georgina V.
Wilmott, James S.
Scolyer, Richard A.
[J]. PIGMENT CELL & MELANOMA RESEARCH, 2021, 34 (03) : 529 - 549
[4] RNA-SeQC: RNA-seq metrics for quality control and process optimization
DeLuca, David S.
Levin, Joshua Z.
Sivachenko, Andrey
Fennell, Timothy
Nazaire, Marc-Danie
Williams, Chris
Reich, Michael
Winckler, Wendy
Getz, Gad
[J]. BIOINFORMATICS, 2012, 28 (11) : 1530 - 1532
[5] STAR: ultrafast universal RNA-seq aligner
Dobin, Alexander
Davis, Carrie A.
Schlesinger, Felix
Drenkow, Jorg
Zaleski, Chris
Jha, Sonali
Batut, Philippe
Chaisson, Mark
Gingeras, Thomas R.
[J]. BIOINFORMATICS, 2013, 29 (01) : 15 - 21
[6] Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment
Gajewski, Thomas F.
Corrales, Leticia
Williams, Jason
Horton, Brendan
Sivan, Ayelet
Spranger, Stefani
[J]. TUMOR IMMUNE MICROENVIRONMENT IN CANCER PROGRESSION AND CANCER THERAPY, 2017, 1036 : 19 - 31
[7] Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, Jerome
Bruni, Daniela
[J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (03) : 197 - 218
[8] Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, Tuba N.
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
[J]. CLINICAL CANCER RESEARCH, 2018, 24 (06) : 1260 - 1270
[9] Whole-genome landscapes of major melanoma subtypes
Hayward, Nicholas K.
Wilmott, James S.
Waddell, Nicola
Johansson, Peter A.
Field, Matthew A.
Nones, Katia
Patch, Ann-Marie
Kakavand, Hojabr
Alexandrov, Ludmil B.
Burke, Hazel
Jakrot, Valerie
Kazakoff, Stephen
Holmes, Oliver
Leonard, Conrad
Sabarinathan, Radhakrishnan
Mularoni, Loris
Wood, Scott
Xu, Qinying
Waddell, Nick
Tembe, Varsha
Pupo, Gulietta M.
De Paoli-Iseppi, Ricardo
Vilain, Ricardo E.
Shang, Ping
Lau, Loretta M. S.
Dagg, Rebecca A.
Schramm, Sarah-Jane
Pritchard, Antonia
Dutton-Regester, Ken
Newell, Felicity
Fitzgerald, Anna
Shang, Catherine A.
Grimmond, Sean M.
Pickett, Hilda A.
Yang, Jean Y.
Stretch, Jonathan R.
Behren, Andreas
Kefford, Richard F.
Hersey, Peter
Long, Georgina V.
Cebon, Jonathan
Shackleton, Mark
Spillane, Andrew J.
Saw, Robyn P. M.
Lopez-Bigas, Nuria
Pearson, John V.
Thompson, John F.
Scolyer, Richard A.
Mann, Graham J.
[J]. NATURE, 2017, 545 (7653) : 175 - 180
[10] Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma
Katsoulakis, Evangelia
Yu, Yao
Apte, Aditya P.
Leeman, Jonathan E.
Katabi, Nora
Morris, Luc
Deasy, Joseph O.
Chan, Timothy A.
Lee, Nancy Y.
Riaz, Nadeem
Hatzoglou, Vaios
Oh, Jung Hun
[J]. ORAL ONCOLOGY, 2020, 110

← 1 2 3 →